Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196)

27.40-0.06-0.22%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Sisram Medical Signs MOU for Localisation Cooperation with Sinmait Medical in China
  Reuters · 41 minutes ago
  Sisram Medical Signs MOU for Localisation Cooperation with Sinmait Medical in China
- Fosun Pharmaceutical Gets Nod for Colorectal Cancer Drug Clinical Trial
  MT Newswires Live · 11:36
  Fosun Pharmaceutical Gets Nod for Colorectal Cancer Drug Clinical Trial
- InSilico Medicine Signs CNS Drug Deal With Hygtia Therapeutics; Shares Up 4%
  MT Newswires Live · 01-20 10:15
  InSilico Medicine Signs CNS Drug Deal With Hygtia Therapeutics; Shares Up 4%
- BRIEF-Shanghai Fosun Pharma Says Drug Application Of Erythromycin Lactobionate For Injection Accepted By NMPA
  Reuters · 01-14
  BRIEF-Shanghai Fosun Pharma Says Drug Application Of Erythromycin Lactobionate For Injection Accepted By NMPA
- Shanghai Fosun Pharma - Drug Application of Erythromycin Lactobionate for Injection Accepted by Nmpa
  THOMSON REUTERS · 01-14
  Shanghai Fosun Pharma - Drug Application of Erythromycin Lactobionate for Injection Accepted by Nmpa
- Fosun Pharma Unit Gets China Acceptance for Lung Cancer Drug Application
  MT Newswires Live · 01-08
  Fosun Pharma Unit Gets China Acceptance for Lung Cancer Drug Application
- BRIEF-Shanghai Fosun Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate Capsules
  Reuters · 01-08
  BRIEF-Shanghai Fosun Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate Capsules
- Shanghai Fosun Pharma - Drug Registration Application of Foritinib Succinate Capsules Accepted by Nmpa
  THOMSON REUTERS · 01-08
  Shanghai Fosun Pharma - Drug Registration Application of Foritinib Succinate Capsules Accepted by Nmpa
- Fosun Pharma's (600196.SH) Controlled Subsidiary Has Drug Registration Application Accepted
  Stock News · 01-08
  Fosun Pharma's (600196.SH) Controlled Subsidiary Has Drug Registration Application Accepted
- Fosun Pharmaceutical-Backed Fund Completes Private Fund Filing
  MT Newswires Live · 01-06
  Fosun Pharmaceutical-Backed Fund Completes Private Fund Filing
- Chengdu Xingrui Jingxuan Therapeutics Launches Phase I Trial for Prostate Cancer Radiopharmaceutical
  Reuters · 2025-12-30
  Chengdu Xingrui Jingxuan Therapeutics Launches Phase I Trial for Prostate Cancer Radiopharmaceutical
- Fosun Pharma's 1.4 Billion Yuan Bet on Discontinued Drug Draws Scrutiny Amid Efficacy Doubts
  Deep News · 2025-12-23
  Fosun Pharma's 1.4 Billion Yuan Bet on Discontinued Drug Draws Scrutiny Amid Efficacy Doubts
- Fosun Pharma's $1.4B Bet on Controversial Alzheimer's Drug: What's the Strategy?
  Deep News · 2025-12-21
  Fosun Pharma's $1.4B Bet on Controversial Alzheimer's Drug: What's the Strategy?
- Fosun Pharma, ClavisBio Sign Five-Year Drug Collaboration Agreement; Shanghai Shares Rise 3%
  MT Newswires Live · 2025-12-19
  Fosun Pharma, ClavisBio Sign Five-Year Drug Collaboration Agreement; Shanghai Shares Rise 3%
- Fosun United Health Insurance Withdraws Announcement of 9 Medical Insurance Plans Covering Innovative Drugs
  Deep News · 2025-12-18
  Fosun United Health Insurance Withdraws Announcement of 9 Medical Insurance Plans Covering Innovative Drugs
- BRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio
  Reuters · 2025-12-18
  BRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio
- Fosun Pharmaceutical Says Could Receive up to $362.5 Mln per Project IF Clavis Bio Exercises Option
  THOMSON REUTERS · 2025-12-18
  Fosun Pharmaceutical Says Could Receive up to $362.5 Mln per Project IF Clavis Bio Exercises Option
- Fosun Pharmaceutical Says Unit Signs Deal With Clavis Bio for Co-Development and Exclusive Licensing Options
  THOMSON REUTERS · 2025-12-18
  Fosun Pharmaceutical Says Unit Signs Deal With Clavis Bio for Co-Development and Exclusive Licensing Options
- FOSUN PHARMA (600196.SH) Subsidiary Signs Collaboration and Option Agreement with Clavis Bio
  Stock News · 2025-12-18
  FOSUN PHARMA (600196.SH) Subsidiary Signs Collaboration and Option Agreement with Clavis Bio
- Fosun Pharma Acquires Green Valley Pharma: A Ray of Hope for Alzheimer's Patients?
  Deep News · 2025-12-16
  Fosun Pharma Acquires Green Valley Pharma: A Ray of Hope for Alzheimer's Patients?
Company Profile
Company Name
上海复星医药(集团)股份有限公司
Industry
医药制造业
Listing Date
1998-08-07
Registered Capital
267042万元
Introduction
上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。

1D
5D
Day
Week
Month

Loading ...

High

27.66

Open

27.43

T/O Rate

0.78%

Low

27.24

27.46

Amplitude

1.53%

To The Moon

Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196)

Company Profile

Most Discussed